The novel sulfonylhydrazine alkylating agent VNP 40101M may be a feasible treatment for patients with relapsed or refractory leukaemia

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1441, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

By Murren John   Modiano Manuel   Kummar Shivaani   Clairmont Caroline   Egorin Merrill   Chu Edward   Sznol Mario  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 123-135

Springer Publishing Company

Access to resources Recommend Favorite

Alvocidib [flavopiridol] may be an effective treatment for patients with refractory chronic lymphocytic leukaemia

By  

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Bexarotene in combination with PUVA may be a treatment option in patients with cutaneous T-cell lymphoma refractory to multiple single-agent therapies

By  

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Clofarabine a lifeline in relapsed and refractory paediatric leukaemia

By  

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite